Financial reports
10-K
2023 FY
Annual report
12 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K
Departure of Directors or Certain Officers
21 Mar 24
8-K
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
12 Mar 24
8-K
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
24 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Other Events
22 Dec 23
8-K
Departure of Directors or Certain Officers
21 Dec 23
8-K
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
14 Nov 23
8-K
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
14 Aug 23
8-K
Heron Therapeutics Announces $30 Million Private Placement Financing
24 Jul 23
8-K
Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
23 Jun 23
Registration and prospectus
424B3
Prospectus supplement
5 Sep 23
S-3
Shelf registration
23 Aug 23
D
$30.00 mm in equity / options, sold $30.00 mm, 7 investors
1 Aug 23
S-8
Registration of securities for employees
30 Jun 23
424B5
Prospectus supplement for primary offering
20 Oct 22
S-3
Shelf registration
7 Oct 22
S-8
Registration of securities for employees
9 Sep 22
S-8
Registration of securities for employees
14 Sep 21
S-3ASR
Automatic shelf registration
28 May 21
424B2
Prospectus for primary offering
7 Oct 19
Proxies
PRE 14A
Preliminary proxy
19 Apr 24
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
20 Apr 23
DEF 14A
Definitive proxy
25 Apr 22
PRE 14A
Preliminary proxy
14 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
23 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Apr 19
Other
EFFECT
Notice of effectiveness
1 Sep 23
CORRESP
Correspondence with SEC
30 Aug 23
UPLOAD
Letter from SEC
28 Aug 23
EFFECT
Notice of effectiveness
19 Oct 22
CORRESP
Correspondence with SEC
13 Oct 22
UPLOAD
Letter from SEC
13 Oct 22
UPLOAD
Letter from SEC
30 Aug 21
CORRESP
Correspondence with SEC
10 Aug 21
UPLOAD
Letter from SEC
15 Jul 21
UPLOAD
Letter from SEC
22 Aug 18
Ownership
4
Ira Duarte
19 Apr 24
4
William P Forbes
19 Apr 24
4
Craig A Collard
19 Apr 24
4
Craig A Collard
5 Apr 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FRANKLIN RESOURCES INC
6 Feb 24
4
Waage Christian
19 Jan 24